First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria

Exclusion Criteria

• •All Parts:
• •1. Any acute or chronic medical condition that would prevent the participant from complying with the procedures or place the participant at risk if they participate in the study.
• •2. Positive for hepatitis B or C or human immunodeficiency virus.
• •3. Any history of malignancy in the last 5 years, excluding non-melanoma skin cancer.
• •4. Any history of liver disease.
• •5. Any surgical or medical conditions that may affect study drug absorption, distribution, metabolism, or excretion.
• •6. Participation in another investigational drug trial within 30 days or, if known, 5 half-lives of the investigational drug (whichever is longer).
• •7. History of drug/alcohol abuse in the last year.
• •8. Current, recent, or suspected infection within 4 weeks of Screening of SARS-CoV-2/COVID-19.
• •9. Received a vaccine for SARS-CoV-2/COVID-19 within 14 days of Screening.
• •10. Unable to tolerate oral medication.
• •11. Allergy to JNT-517 or any component of the investigational product.
• •12. Received \>50 mL of blood or plasma within 30 days of Screening or \>500 mL of blood or plasma within 60 days of Screening.